Abstract: The present invention provides a pharmaceutical composition comprising a protein having ?-galactosidase activity for treating Fabry disease, which causes no allergic side effect, which is highly stable in blood (plasma) and which can readily be taken up by a cell of an affected organ. The pharmaceutical composition for treating Fabry disease of the invention comprises, for example, a protein which acquires an ?-galactosidase activity through alteration of the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.
Type:
Grant
Filed:
September 13, 2013
Date of Patent:
April 19, 2016
Assignees:
TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE, ALTIF LABORATORIES INC.
Abstract: Soluble PH20 polypeptides are provided, including extended soluble PH20 polypeptides, and uses thereof. Also provided are other C-terminally truncated PH20 polypeptides and partially deglycosylated PH20 polypeptides and uses thereof.
Type:
Grant
Filed:
February 21, 2012
Date of Patent:
March 15, 2016
Assignee:
Halozyme, Inc.
Inventors:
Ge Wei, Krishnasamy Panneer Selvam, Louis Bookbinder, Gregory I. Frost
Abstract: Proteases encompassing an amino acid sequence, which are at least 70% identical to the amino acid sequence specified in SEQ ID NO. 1 over the entire length thereof and which, in the listing according to SEQ ID NO. 1, have the amino acid substitution I21V in combination with at least one further amino acid substitution, the further amino acid substitution being selected from the group consisting of Q12L, M122L, N177V, A222S, V228I and T247N, and agents encompassing such proteases, exhibit very good cleaning performance on egg-containing stains.
Type:
Grant
Filed:
September 9, 2013
Date of Patent:
February 16, 2016
Assignee:
HENKEL AG & CO. KGAA
Inventors:
Susanne Wieland, Petra Siegert, Timothy O'Connell, Karl-Heinz Maurer, Ronny Martinez, Ulrich Schwaneberg, Hendrik Hellmuth
Abstract: A novel Src inhibitor that targets the Na/K-ATPase/Src receptor complex and antagonizes ouabain-induced protein kinase cascades and uses thereof are disclosed.
Type:
Grant
Filed:
March 3, 2014
Date of Patent:
January 5, 2016
Assignee:
The University of Toledo
Inventors:
Zi-Jian Xie, Zhichuan Li, Joseph I. Shapiro
Abstract: Disclosed is a novel method for detecting interactions of biomolecules. More particularly, the disclosed method includes (a) preparing a cell comprising (i) a first construct comprising a bait, a first labeling material and a translocation module; and (ii) a second construct comprising a prey and a second labeling material; (b) detecting the distribution of the first construct and the second construct in the cell. the present invention provides a method capable of detecting bindings and interactions occurring in a living cell in real time, and a method for screening a material that alters the binding and the interaction. The method of the present invention overcomes the disadvantages including inaccuracy and complexity of existing biomaterial interaction detection techniques. By labeling both constructs to promote accuracy, the present invention provides a novel real-time, antibody-free analysis.
Abstract: The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of non-chronic or chronic inflammatory digestive diseases, such as colitis, including e.g. Ulcerative colitis, Crohn's disease, diversion colitis, ischemic colitis, infectious colitis, fulminant colitis, chemical colitis, microscopic colitis, lymphocytic colitis, and atypical colitis, etc.
Abstract: The present invention provides protease variants, compositions comprising protease variants, and methods of using such protease variants and compositions.
Type:
Grant
Filed:
March 25, 2014
Date of Patent:
October 13, 2015
Assignee:
DANISCO US INC.
Inventors:
Joshua Roy Basler, Luis Gustavo Cascao-Pereira, David A. Estell, James T. Kellis, Jr., Alexander Pisarchik, Ayrookaran J. Poulose, Daniel Torres-Pazmino
Abstract: The invention pertains to a cyclic peptide comprising the following sequence: -S1-X1-S2-X2- wherein S1 is a first target peptide sequence of a protease enzyme E1, S2 is a second target peptide sequence of a protease enzyme E2, S1 and S2 possibly being the same or different, said first peptide sequence S1 and said second peptide sequence S2 comprising 4 to 14 amino acids, E1 and E2 possibly corresponding to the same protease enzyme or to two different protease enzymes, X1 is a probe carrying a fluorescent donor group and X2 is a probe carrying a fluorescent or non-fluorescent acceptor group. Application of these peptides to determination of the activity of protease enzymes.
Type:
Grant
Filed:
June 10, 2009
Date of Patent:
September 22, 2015
Assignees:
COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, UNIVERSITE VICTOR SEGALEN-BORDEAUX 2
Abstract: The invention relates to tPA mutant devoid of protease activity and uses thereof in compositions and methods for the treatment and prevention of pathologic conditions involving neurological injury or an ischemic disease or condition. More specifically, the invention relates to a Ser481 to Ala mutant of tPA and to compositions and combinations thereof for the treatment of stroke, acute brain injury and neurodegenerative disorders. The invention further provides methods and kits for the treatment of said disorders.
Type:
Grant
Filed:
March 16, 2009
Date of Patent:
July 7, 2015
Assignee:
HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD.
Abstract: Provided herein are methods and compositions relating to the synthesis of isoprenoid diphosphates using a mutated isopentenyl phosphate kinase.
Abstract: The present invention relates, in general, to Glycogen Storage Disease and, in particular, to a method of treating Glycogen Storage Disease-type-III and to compounds and compositions suitable for use in such a method.
Type:
Grant
Filed:
July 8, 2009
Date of Patent:
June 9, 2015
Assignee:
DUKE UNIVERSITY
Inventors:
Yuan-Tsong Chen, Priya Kishnani, Baodong Sun
Abstract: Objects of the present invention are to provide a DNA fragment encoding a limulus-derived pro-clotting enzyme, a virus harboring the DNA fragment, a cell harboring the virus, a method of producing the pro-clotting enzyme by use of the cell, and means for assaying an endotoxin or (1?3)-?-D-glucan employing the enzyme, wherein these elements are capable of producing an endotoxin or (1?3)-?-D-glucan assay reagent of satisfactory quality, steadily, at low cost, and on a large scale. In the present invention, for example, a DNA fragment encoding a protein having an amino acid sequence defined by SEQ ID NO: 4 is selected as a nucleic acid fragment encoding a limulus-derived pro-clotting enzyme, and the corresponding recombinant pro-clotting enzyme. Use of the enzyme can provide a high-sensitivity method and kit for detecting (1?3)-?-D-glucan and an endotoxin, utilizing a cascade reaction system in a horseshoe crab lysate.
Abstract: The present invention relates to proteases having at least 75% identity to a protease derived from Thermoascus aurantiacus and comprises at least one modification in the amino acid sequence thereof. These protease variants have improved thermostability. The invention also relates to DNA encoding these proteases, methods of their production, as well as the use thereof.
Type:
Grant
Filed:
December 10, 2010
Date of Patent:
May 26, 2015
Assignee:
NOVOZYMES A/S
Inventors:
Tomoko Matsui, Allan Noergaard, Thomas Agersten Poulsen, John Matthews
Abstract: Objects of the present invention are to provide a DNA fragment encoding a limulus-derived pro-clotting enzyme, a virus harboring the DNA fragment, a cell harboring the virus, a method of producing the pro-clotting enzyme by use of the cell, and means for assaying an endotoxin or (1?3)-?-D-glucan employing the enzyme, wherein these elements are capable of producing an endotoxin or (1?3)-?-D-glucan assay reagent of satisfactory quality, steadily, at low cost, and on a large scale. In the present invention, for example, a DNA fragment encoding a protein having an amino acid sequence defined by SEQ ID NO: 4 is selected as a nucleic acid fragment encoding a limulus-derived pro-clotting enzyme, and the corresponding recombinant pro-clotting enzyme. Use of the enzyme can provide a high-sensitivity method and kit for detecting (1?3)-?-D-glucan and an endotoxin, utilizing a cascade reaction system in a horseshoe crab lysate.
Abstract: The invention describes isolated mTOR-associated proteins (“mTOR-APs”) as well as isolated variants and fragments thereof and the isolated nucleic acids encoding them. The invention also describes vectors and host cells containing nucleic acid encoding an mTOR-AP polypeptide and methods for producing an mTOR-AP polypeptide. Also described are methods for screening for compounds which modulate mTOR-AP activity and methods for treating or preventing a disorder that is responsive to mTOR-AP modulation.
Type:
Grant
Filed:
August 13, 2012
Date of Patent:
April 7, 2015
Assignee:
Whitehead Institute for Biomedical Research
Inventors:
David M. Sabatini, Do-Hyung Kim, Dos D. Sarbassov
Abstract: The present invention relates to isolated polypeptides having cellulase activity. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
Type:
Grant
Filed:
August 10, 2012
Date of Patent:
April 7, 2015
Assignee:
Novozymes A/S
Inventors:
Kirk Matthew Schnorr, Lars Anderson, Maria Leonor Quintais Cancela Da Fonseca, Ricardo Leite
Abstract: The present invention relates to mutants of a parent Trichoderma strain, comprising a polynucleotide encoding a polypeptide and one or more (several) genes selected from the group consisting of a first subtilisin-like serine protease gene, a first aspartic protease gene, a trypsin-like serine protease gene, a second subtilisin-like serine protease gene, and a second aspartic protease gene, wherein the one or more (several) genes are modified rendering the mutant strain deficient in the production of one or more (several) enzymes selected from the group consisting of a first subtilisin-like serine protease, a first aspartic protease, a trypsin-like serine protease, a second subtilisin-like serine protease, and a second aspartic protease, respectively, compared to the parent Trichoderma strain when cultivated under identical conditions. The present invention also relates to methods of producing a polypeptide in such mutants and methods for producing such mutants.
Abstract: A method for regulating Src and its downstream signaling pathway which includes binding between Src and Na+/K+-ATPase is disclosed. The Na+/K+-ATPase/Src complex is a functional receptor for cardiotonic steroids such as ouabain. Also disclosed are Src inhibitors or activators which include either Na+/K+-ATPase or Src that interfere with the interaction between the Na/K-ATPase and Src, act via a different mechanism from ATP analogs, and is pathway (Na+/K+-ATPase) specific.
Type:
Grant
Filed:
September 24, 2012
Date of Patent:
March 17, 2015
Assignee:
The University of Toledo
Inventors:
Zi-Jian Xie, Joseph I. Shapiro, Jiang Tian, Zhichuan Li
Abstract: The present invention relates to novel Prolipase-Bovine trypsinogen (PLBTR) fusion proteins, the genes encoding them, and the production and uses thereof. More specifically, the present invention relates to methods of producing in optimal quantities PLBTR fusion proteins which comprise a heterologous polypeptide which is normally susceptible to autocatalytic activity. More particularly, the present invention relates to fusion proteins which comprise an heterologous polypeptide, such as a serine protease, fused to a lipase signal sequence, which can be expressed by recombinant host cells in desired amounts. The present invention further relates to polynucleotides encoding such fusion proteins, to expression vectors for expression of such fusion proteins, to host cells transformed with such polynucleotides/vectors, and to methods of generating such fusion proteins.
Abstract: The invention relates to recombinant expression vectors encoding a low molecular weight peptide isolated from the submaxiliary saliva glands of shrews of the species Blarina as a paralytic agent. This novel paralytic agent is useful as a neuromuscular blocker and analgesic or as an insecticide.
Type:
Grant
Filed:
March 13, 2014
Date of Patent:
February 24, 2015
Assignee:
Soricimed Biopharma Inc.
Inventors:
John M Stewart, Bradley J Steeves, Karl Vernes